

LumiraDx launches POC test to help combat antimicrobial resistance in India

24 November 2022 | News

LumiraDx CRP diagnostic test combines speed and test sensitivity at the point of need, empowering doctors to make informed decisions on antibiotic prescriptions

UK-based LumiraDx Healthcare has launched its highly sensitive C-Reactive Protein (CRP) point of care (POC) antigen test across India. The point of care CRP test can be used in multiple clinical settings to help reduce unnecessary antibiotic prescribing that leads to antimicrobial resistance (AMR). From a tiny sample of finger-prick blood, the CRP test gives results within four minutes on the portable LumiraDx platform which weighs just over a kilogram.

Studies show that point of care CRP testing reduces antibiotic prescribing by 23-36% for respiratory tract infections (RTI), and 22% for chronic obstructive pulmonary disease (COPD).

In India, CRP tests are available in intensive care units (ICUs), paediatric departments, outpatient departments (OPDs), and other clinical care settings. The Government of India considers AMR a priority health issue and has undertaken a nationwide initiative by launching an AMR stewardship programme.